Lucerna awarded $313,148 by NIH for DM1 drug discovery platform

🧪 Oasis Diagnostics Corporation — 23 Years of Innovation in Saliva & Non-Invasive Collection Technologies For over two decades, Oasis Diagnostics Corporation has been at the forefront of saliva collection, testing, stabilization, and storage technologies. Our innovative and cost-effective tools support the collection of: 🧬 Proteins, DNA, RNA, and cell-free specimens (cfDNA, cfRNA, exosomes, proteins) 💧 Hormones, drugs of abuse, metabolites, and other biomarkers from saliva 🧪 Urine specimens with long term stability Our collection devices are used across diverse populations — from intubated infants to geriatric patients, and even across multiple animal species (from wood rats to horses). 🚀 With support from a $7.5M NIH / RADx contract, Oasis has scaled to produce up to 2.2 million units per month, ensuring we can meet the demands of both research and large-scale public health initiatives. 🌐 Learn more: www.4saliva.com #OasisDiagnostics #SalivaTesting #NonInvasiveDiagnostics #LifeSciences #BiotechInnovation #RADx #SalivaCollection #Diagnostics #MolecularTesting #PCR #Research

Proud to collaborate with Oasis Diagnostics Corporation, a global leader in innovative non-invasive sample collection technologies. At Tiaris Biosciences, we are the official distributor of Oasis Diagnostics in Spain and Portugal, expanding our portfolio with their comprehensive solutions for the non-invasive collection and stabilization of DNA/RNA and other biomarkers for researchers and professionals. 🧬🧬🧬

Meet with Andrea O'Hara, Ph.D. and nRichDX at #ASHG25 (10/16 2:30PM ET) to learn about "cfRNA Cryptic Intron Identification from Liquid Biopsy Samples". Quick summary of the poster session below 👇 Amyotrophic lateral sclerosis (ALS) is a rare, terminal neurodegenerative disorder that results in the progressive loss of both upper and lower motor neurons that normally control voluntary muscle contraction. Cell-free nucleic acids can be used as robust biomarkers to determine disease development and progression, with liquid biopsy being an efficient method to detect specific cfRNA. Specifically, cfRNA can be utilized to detect cryptic introns: an intron that is not spliced out and is released into the blood stream in patients with ALS. Learn more and explore our other activities at ASHG: https://hubs.ly/Q03Ngc150 Azenta Life Sciences #LiquidBiopsy #Intron #ALS #GWZASHG

October is #NationalLiverAwarenessMonth..today & everyday, early detection matters more than ever. We, Taiba Medserv partner with innovation leaders to deliver precision diagnostics for liver disease. Using QIAGEN’s Sample technology solutions (which support high-yield nucleic acid isolation from liver tissue among other sample types) we ensure clean, high-quality nucleic acid starting material. Then Illumina’s sequcing solutions including NGS platform and library preparation kits gives labs the genomic insights to detect fibrosis markers, viral genotypes, and early molecular changes in liver disease. Together, QIAGEN and Illumina form a workflow from sample to sequence and Taiba Medserv brings these tools into regional labs so healthcare providers can act sooner, smarter with better patient outcomes. Contact us to know more: +968 71523992 #MakingHealthcareAccessibleInOman #TaibaMedserv #LiverAwarenessMonth #Qiagen #Illumina #OmaniHealthcareDistributors #GenomicsForHealth #MolecularDiagnostics #PrecisionMedicine #EarlyDiagnosis #LiverHealth #NextGenSequencing

We're excited to announce the launch of our new GenoSphere™ MASH-enriched cohort – comprising over 17,000 linked clinico-genomic records with deep Exome+® sequencing and longitudinal EHR data. With MASH affecting ~22 million adult Americans and highly associated with cardiometabolic comorbidities, this expansive dataset represents a significant leap forward in advancing drug discovery and development for this severe liver condition. Key features include: 📊 Comprehensive clinical data 🧪 10+ disease-specific labs 📈 Clinical severity scores (FIB-4, APRI, NFS) 📋 An average of 15 years of EHR history per participant Fueled by the Helix Research Network, the largest precision health network in North America, we're helping researchers and drug developers identify the key insights needed to create more effective and targeted treatments. Read our press release to learn more: https://lnkd.in/gpJd8Rtb #Genomics #PrecisionMedicine #DrugDiscovery #MASH

The recording and slides from “Accelerating #DrugDiscovery for #MASLD Using High Content Imaging” are now available: https://hubs.ly/Q03QLwRg0 Advanced #invitro models are successfully being used to study the mechanisms of Metabolic Dysfunction-Associated Steatotic #LiverDisease (MASLD). Karissa Cottier, PhD discussed studies utilizing #HEPATOPAC® cultures to model aspects of fatty liver disease to enable the evaluation of potential therapeutic targets, including small molecules and siRNA-based approaches, to modulate disease progression. These studies highlight the use of high content imaging (HCI) as a method for automating and increasing throughput for these analyses. Access this insightful presentation and more: https://hubs.ly/Q03QLwRg0

𝑾𝒉𝒂𝒕 𝒊𝒇 𝑷𝒂𝒓𝒌𝒊𝒏𝒔𝒐𝒏’𝒔 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕 𝒅𝒊𝒅𝒏’𝒕 𝒋𝒖𝒔𝒕 𝒎𝒂𝒏𝒂𝒈𝒆 𝒔𝒚𝒎𝒑𝒕𝒐𝒎𝒔 — 𝒃𝒖𝒕 𝒓𝒆𝒑𝒍𝒂𝒄𝒆𝒅 𝒕𝒉𝒆 𝒏𝒆𝒖𝒓𝒐𝒏𝒔 𝒕𝒉𝒂𝒕 𝒘𝒆𝒓𝒆 𝒍𝒐𝒔𝒕? As a movement scientist, I closely follow novel and innovative therapies that have the potential to redefine how we treat neurological diseases. The question above is being explored in a new Phase 1/2a clinical trial using 𝐚𝐮𝐭𝐨𝐥𝐨𝐠𝐨𝐮𝐬 𝐢𝐏𝐒𝐂–𝐝𝐞𝐫𝐢𝐯𝐞𝐝 𝐝𝐨𝐩𝐚𝐦𝐢𝐧𝐞𝐫𝐠𝐢𝐜 𝐧𝐞𝐮𝐫𝐚𝐥 𝐩𝐫𝐞𝐜𝐮𝐫𝐬𝐨𝐫 𝐜𝐞𝐥𝐥𝐬 — developed by Aspen Neuroscience, Inc. The company just announced Cohort 3 initiation in its ASPIRO Phase 1/2a trial of ANPD001, marking the first use of a 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥-𝐬𝐜𝐚𝐥𝐞, 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 of this cell therapy. 6-month data are available for three patients enrolled in their first cohort, and results are encouraging. (Link: https://lnkd.in/ePxBiEkw) 𝐓𝐡𝐞 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ➤ 𝐒𝐚𝐟𝐞𝐭𝐲 & 𝐓𝐨𝐥𝐞𝐫𝐚𝐛𝐢𝐥𝐢𝐭𝐲: No hemorrhages, surgical complications, or graft-induced dyskinesia were observed. ➤ 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬: ✅ Participants showed an average 45% 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭 𝐢𝐧 𝐌𝐃𝐒-𝐔𝐏𝐃𝐑𝐒 𝐏𝐚𝐫𝐭 𝐈𝐈𝐈 (“off” motor) scores and a 71% 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭 𝐢𝐧 𝐏𝐚𝐫𝐭 𝐈𝐈 (𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐢𝐞𝐬 𝐨𝐟 𝐝𝐚𝐢𝐥𝐲 𝐥𝐢𝐯𝐢𝐧𝐠), which 𝐞𝐱𝐜𝐞𝐞𝐝 𝐦𝐢𝐧𝐢𝐦𝐚𝐥 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬 (𝐌𝐂𝐈𝐃𝐬) by a factor of 3-5! ✅ “Off time” decreased by about 2 hours per day, while “good on” time increased by 1.5 hours. ➤ 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 — ANPD001 directly targets the cellular loss underlying PD, representing a major step in regenerative neuroscience. Just as human neural stem cells are showing promise in preclinical stroke models (see my previous post), this PD trial is taking the next step — 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐚𝐭 𝐫𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐜𝐥𝐢𝐧𝐢𝐜. 🧠💬 𝘏𝘰𝘸 𝘥𝘰 𝘺𝘰𝘶 𝘴𝘦𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵-𝘥𝘦𝘳𝘪𝘷𝘦𝘥 𝘯𝘦𝘶𝘳𝘰𝘯𝘴 𝘳𝘦𝘥𝘦𝘧𝘪𝘯𝘪𝘯𝘨 𝘩𝘰𝘸 𝘸𝘦 𝘵𝘳𝘦𝘢𝘵 𝘯𝘦𝘶𝘳𝘰𝘥𝘦𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘷𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦? #ParkinsonsDisease #Neuroregeneration #StemCellTherapy #iPSCs #RegenerativeMedicine

We had a full team from #Viralgen in Sevilla last week for #ESGCT2025. And when we compared notes from yet another informative, inspiring conference, four key takeaways emerged from our discussions: ✓ 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 & 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻: The development of capsids with targeted tropism and immune evasion will enable more personalized and effective therapies, especially for CNS, muscle, retina, and hard-to-target organs. ✓ 𝗥𝗲𝗱𝗼𝘀𝗶𝗻𝗴 & 𝗔𝗰𝗰𝗲𝘀𝘀: Strategies for #AAV redosing and immune evasion are critical to expand patient eligibility and clinical impact. ✓ 𝗦𝗮𝗳𝗲𝘁𝘆 & 𝗠𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴: Deep analysis of integration, immunogenicity, and genotoxicity remain a top priority for clinical consolidation of AAV therapies. ✓ 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴: Adoption of synthetic DNA, intensified bioprocesses, and automated platforms are seen as essential to reduce costs and accelerate patient access. What could all this mean for your plans to advance your #genetherapy? Let’s talk and find out together. We’ll see you next year in Hamburg at #ESGCT2026 – and, between now and then, everywhere else that industry leaders are meeting to put the best possible AAV science to work for their patients.   #CellAndGeneTherapy #BiotechEvents #CDMO #CGT

At Forbion, we believe that innovation in rare diseases is among the most meaningful and transformative in all of life sciences. This week, we hosted our second annual Excellence Roundtable, dedicated to exploring the future of innovation in rare diseases. The discussion brought together a diverse group of leaders, from patient advocates and biotech executives to investors and scientists, to share their experiences and perspectives on advancing therapies for patients with rare conditions. Chaired by Charis Gresser (Brunswick Group), the panel featured: Tanya Collin-Histed, CEO, International Gaucher Alliance Yann Le Cam, Founder & Past-CEO, EURORDIS-Rare Diseases Europe Stefano Portolano, MD, CEO, AZAFAROS B.V. Carlo Incerti, MD, Operating Partner, Forbion Geert-Jan Mulder, Managing Partner, Forbion One of the most powerful themes of the conversation was the central role of patient advocacy in shaping the future of rare disease research. From helping design clinical trials that reflect the realities of patients’ lives, to developing registries and outcome measures that capture meaningful change, patient organizations are now essential partners in the R&D process. Their lived experience ensures that innovation stays grounded in what truly matters, improving quality of life, independence, and hope. As our panellists reminded us, rare disease research is not for the faint-hearted. It demands persistence, creativity, and collaboration, but it also delivers some of the most inspiring breakthroughs in medicine. Over 7,000 rare diseases have been identified, affecting an estimated 350 million people worldwide, and while over 90% still lack approved treatments, the progress achieved in recent decades has been extraordinary. Today, advances in gene and cell therapy, RNA and protein replacement technologies, and digital tools like AI-driven clinical trials are opening new frontiers, and the collective effort of scientists, advocates, investors, and entrepreneurs is turning possibility into progress. Watch our 5-minute video summary to hear the key takeaways from this inspiring conversation and see how patient voices and scientific innovation are working hand in hand to shape the next chapter in rare disease treatment. If you are passionate about driving innovation in rare diseases or would like to join us at similar events in the future, subscribe to our newsletter on https://forbion.com/ #RareDiseases #Biotech #Innovation #LifeSciences #PatientAdvocacy #ForbionExcellenceRoundtable #Impact

Tomas et al. (2019) Assessing cellular energy dysfunction in ME/CFS using a commercially available laboratory test.   Biomarker research is important because biomarkers—measurable biological indicators of disease—may help diagnose ME/CFS.   This is one of several studies that needs replication before any firm conclusions can be made as to its accuracy and to ensure it is specific to ME/CFS.   Read more about the study, funded by the ME Association's Ramsay Research Fund, here:   https://lnkd.in/dTTWDSVw   #MECFS #MyalgicEncephalomyelitis #MEAssociation #RamsayResearchFund #Research